NSE - Delayed Quote INR

Hikal Limited (HIKAL.NS)

Compare
358.05
-13.60
(-3.66%)
At close: January 10 at 3:30:02 PM GMT+5:30
Loading Chart for HIKAL.NS
DELL
  • Previous Close 371.65
  • Open 367.40
  • Bid --
  • Ask --
  • Day's Range 356.50 - 379.85
  • 52 Week Range 260.30 - 464.75
  • Volume 284,789
  • Avg. Volume 634,336
  • Market Cap (intraday) 44.154B
  • Beta (5Y Monthly) 1.25
  • PE Ratio (TTM) 60.28
  • EPS (TTM) 5.94
  • Earnings Date Feb 6, 2025 - Feb 10, 2025
  • Forward Dividend & Yield 1.20 (0.32%)
  • Ex-Dividend Date Sep 4, 2024
  • 1y Target Est 435.00

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredients (APIs). Its Crop Protection segment manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. The company also collaborates with other companies; and offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. In addition, it offers human health products, such as anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-hypertensive, anti-inflammation, and analgesic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

www.hikal.com

2,061

Full Time Employees

March 31

Fiscal Year Ends

Recent News: HIKAL.NS

View More

Performance Overview: HIKAL.NS

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

HIKAL.NS
6.18%
S&P BSE SENSEX
1.11%

1-Year Return

HIKAL.NS
19.90%
S&P BSE SENSEX
8.39%

3-Year Return

HIKAL.NS
34.37%
S&P BSE SENSEX
29.52%

5-Year Return

HIKAL.NS
212.55%
S&P BSE SENSEX
86.67%

Compare To: HIKAL.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HIKAL.NS

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    44.15B

  • Enterprise Value

    51.49B

  • Trailing P/E

    60.08

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.45

  • Price/Book (mrq)

    3.67

  • Enterprise Value/Revenue

    2.85

  • Enterprise Value/EBITDA

    17.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.76%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    18.03B

  • Net Income Avi to Common (ttm)

    678M

  • Diluted EPS (ttm)

    5.94

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    208.8M

  • Total Debt/Equity (mrq)

    68.84%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: HIKAL.NS

View More

People Also Watch